The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Blinatumomab, a TCE targeting CD19 and CD3, was the first bsAb to receive US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval (in 2014 and 2015, respectively) for the ...

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas Pancreatic ...

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) R1 compared induction ...

Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population Adj PD-1 therapy did not improve ...

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma The AI models predicted disease-free survival ...

Natural and Assisted Conceptions in Male Patients With Blood Cancers Who Stored Their Semen for Fertility Preservation It is in this environment that the present JCO Oncology Practice publication of ...

Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm To truly attain high-quality, goal-congruent care at the end of life, collaborations with patients, their ...

Cancers are predominantly characterized by their genomic aberrations, but over the past decades, there has also been an increasing focus on epigenetic alterations in cancer biology. 12-15 Although ...

Patterns of Complementary Medicine Utilization in Patients With Breast Cancer and Colorectal Cancer: A Cross-Sectional Study at a Tertiary Referral Hospital in Yogyakarta, Indonesia A total of 819 ...

Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment Twenty-eight ...

An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last The review by Hazim et al 1 in this journal outlines ongoing and planned major clinical trials in extensive-stage ...